PTC Therapeutics Inc
NASDAQ:PTCT

Watchlist Manager
PTC Therapeutics Inc Logo
PTC Therapeutics Inc
NASDAQ:PTCT
Watchlist
Price: 73.07 USD 0.81% Market Closed
Market Cap: 5.9B USD

Operating Margin

52.5%
Current
Improving
by 68.6%
vs 3-y average of -16.1%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
52.5%
=
Operating Income
$933.2m
/
Revenue
$1.8B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
52.5%
=
Operating Income
$933.2m
/
Revenue
$1.8B

Peer Comparison

Country Company Market Cap Operating
Margin
US
PTC Therapeutics Inc
NASDAQ:PTCT
5.8B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
178.1B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
154.2B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.3B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.7B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.9B USD
Loading...
No Stocks Found

Market Distribution

Higher than 97% of companies in the United States of America
Percentile
97th
Based on 14 112 companies
97th percentile
52.5%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

PTC Therapeutics Inc
Glance View

Market Cap
5.9B USD
Industry
Biotechnology

Nestled in the heart of the biotechnology sector, PTC Therapeutics Inc. has carved a distinctive niche by foregrounding innovative genetic approaches to combat rare diseases. Founded in 1998, the company harnesses the power of science and technology to address unmet medical needs, focusing primarily on disorders originating from genetic mutations that disrupt cellular systems. At its core, PTC leverages its expertise in the discovery and development of small molecule drugs and gene therapies, an endeavor propelled by its proprietary technology platforms such as SmRT (suppressor of nonsense mutations readthrough) and dystrophin restoration technologies. These platforms enable PTC to target and modify specific gene expressions, offering potential treatments for conditions such as Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA), which have historically eluded effective therapies. The company’s revenue generation pivots on two key streams: product sales and strategic collaborations. By marketing its FDA-approved therapies like Translarna and Emflaza for rare genetic disorders, PTC secures a steady flow of income that underscores its sustainable business model. Additionally, PTC forms strategic alliances and collaborative agreements with pharmaceutical giants, fostering a vibrant environment of shared knowledge and resources. These partnerships not only bolster its research and development capabilities but also offer potential milestone payments and royalties, further strengthening its financial portfolio. In this symbiotic landscape, PTC Therapeutics continues to navigate the complexities of biotech development, striving to transform the challenges of rare diseases into treatment opportunities, thereby weaving innovation into the very fabric of business efficacy.

PTCT Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
52.5%
=
Operating Income
$933.2m
/
Revenue
$1.8B
What is PTC Therapeutics Inc's current Operating Margin?

The current Operating Margin for PTC Therapeutics Inc is 52.5%, which is above its 3-year median of -16.1%.

How has Operating Margin changed over time?

Over the last 3 years, PTC Therapeutics Inc’s Operating Margin has increased from -47.6% to 52.5%. During this period, it reached a low of -62.1% on Mar 31, 2023 and a high of 52.5% on Sep 30, 2025.

Back to Top